Compare Direxion Daily Semiconductor Bull 3X Shares (SOXL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bull 3X Shares vs TG Therapeutics Inc — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $147.82, while TG Therapeutics Inc trades at $48.74 (market cap $7.58B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| SOXL | TGTX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $59.06 |
52-Week Low | $24.91 | $26.94 |
Market Cap | — | $7.58B |
Enterprise Value | — | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXL, the Direxion Daily Semiconductor Bull 3X Shares ETF, surged 9.35% to $142.16 amid renewed semiconductor sector optimism. The ETF remains in a technical bearish trend despite the daily rally, with moving averages signaling caution. Recent news highlights significant government semiconductor funding and AI-driven demand catalysts, though the leveraged structure amplifies volatility risks. Financial ratios are unavailable as this is a leveraged ETF tracking semiconductor stocks rather than a traditional company.
SOXL offers aggressive exposure to semiconductor sector rebounds but carries elevated risk due to 3x daily leverage. The current technical setup suggests caution despite positive sentiment around AI chip demand. Key risks include sector volatility, leverage decay, and geopolitical tensions affecting semiconductor supply chains. Investors should understand the specialized nature of leveraged ETFs before considering positions.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
